¿Por qué la pioglitazona deber ser considerada un fármaco cardioprotector? Numerosos estudios han demostrado que la Pioglitazona disminuye el riesgo MACE, de infarto agudo de miocardio y de ACV. Ya en el año 2005 el estudio PROACTIVE demostró una reducción del 16% del compuesto Muerte + IAM no fatal + ACV no fatal (HR 0.84, … Continue reading
The prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis (NAFLD/NASH) is increasing. NAFLD/NASH may progress to cirrhosis and hepatocellular carcinoma. However, most patients with NAFLD/NASH will die from a vascular cause. There are no approved pharmacological treatments for NASH/NAFLD. Many clinical trials have been, or are being, undertaken; however, the challenge is the assessment of the clinical endpoint. The main objective of this narrative review was to evaluate the efficacy of drugs used in clinical trials for the treatment of NAFLD/NASH that included a liver biopsy as the gold standard… Continue reading
Publicamos esta revisión sobre la evidencia disponible en el uso de pioglitazona como tratamiento en diabetes 2. Documenta el modo en que el fármaco disminuye los niveles de glucemia y mejora la protección de eventos cardiovasculares a un costo accesible. El análisis firmado por los especialistas Ralph DeFronzo, Silvio Inzucchi, Steven E Nissen y Muhammad … Continue reading
Patients with ischemic stroke or transient ischemic attack (TIA) are at increased risk for future cardiovascular events despite current preventive therapies. The identification of insulin resistance as a risk factor for stroke and myocardial infarction raised the possibility that pioglitazone, which improves insulin sensitivity, might benefit patients with cerebrovascular disease… Continue reading
Impaired glucose tolerance (IGT) is a prediabetic state. If IGT can be prevented from progressing to overt diabetes, hyperglycemia-related complications can be avoided. The purpose of the present study was to examine whether pioglitazone (ACTOS®) can prevent progression of IGT to type 2 diabetes mellitus (T2DM) in a prospective randomized, double blind, placebo controlled trial… Continue reading
Abstract Nonalcoholic fatty liver disease (NAFLD) is considered the most common liver disorder in the Western world. It is commonly associated with insulin resistance, obesity, dyslipidaemia, type 2 diabetes mellitus (T2DM) and cardiovascular disease. Nonalcoholic steatohepatitis (NASH) is characterized by steatosis with necroinflammation and eventual fibrosis, which can lead to end-stage liver disease and hepatocellular … Continue reading
A simple and rapid high performance liquid chromatography–tandem mass spectrometry (LC-MS/MS) method was developed for the simultaneous determination of pioglitazone and its active metabolites hydroxypioglitazone and ketopioglitazone in human plasma… Continue reading
Background The metabolic defects of nonalcoholic steato-hepatitis (NASH) and prediabetes or type 2 diabetes mellitus (T2DM) seem to be specifically targeted by pioglitazone. However, information about its long-term use in this population is limited… Continue reading
Objectives: Describe and compare the risk of cardiovascular and non-cardiovascular mortality in patients whose antidiabetic therapy is modified to include
pioglitazone compared with an alternative antidiabetic
medication at the same stage of disease progression… Continue reading
Objectives To evaluate the effect of pioglitazone in people with insulin resistance, pre-diabetes and type 2diabetes. Design and setting: Systematic review and meta-analysis of randomised, controlled trials. Data sources: Literature searches were performed across PubMed, EMBASE, MEDLINE and Cochrane Central Register of Controlled Trials from 1966 to May 2016 to identify randomised, controlled trials with … Continue reading
Impaired glucose tolerance is associated with increased rates of cardiovascular disease and conversion to type 2 diabetes mellitus. Interventions that may prevent or delay such occurrences are of great clinical importance… Continue reading
Type 2 diabetes is caused by insulin resistance coupled with an inability to produce enough insulin to control blood glucose, and thiazolidinediones (TZDs) are the only current antidiabetic agents that function primarily by increasing insulin sensitivity. However, despite clear benefits in glycemic control, this class of drugs has recently fallen into disuse due to concerns over side effects and adverse events. Here we review the clinical data and attempt to balance the benefits and risks of TZD therapy. We also examine potential mechanisms of action for the beneficial and harmful effects of TZDs, mainly via agonism of the nuclear receptor PPARg… Continue reading
El material incluido en sección ha sido concebido exclusivamente para los profesionales de la salud con fines informativos, y destinado a orientar sobre el uso adecuado de los medicamentos y a satisfacer sus necesidades de mayor información.
Laboratorios Francelab le sugiere consultar siempre a un profesional de la salud calificado ante cualquier duda sobre una condición médica particular.
